Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.

Apoptosis : an international journal on programmed cell death - 1 Apr 2020

Li Kezhu, Tang Mingrui, Tong Shuang, Wang Chenchao, Sun Qiang, Lv Mengzhu, Sun Xu, Wang Ting, Jin Shifeng

Abstract excerpt

Treatment of advanced BRAFV600-mutant melanoma using BRAF inhibitors (BRAFi) eventually leads to drug resistance and selects for highly metastatic tumor cells. We compared the most differentially dysregulated miRNA expression profiles of vemurafenib-resistant and highly-metastatic melanoma cell lines obtained from GEO DataSets. We discovered miR-152-5p was a potential regulator mediating melanoma drug resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 32056038
DOI: 10.1007/s10495-019-01586-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.PMID 32056038Read ↗

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanomaSemantic proximity Read ↗

MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.Semantic proximity Read ↗

Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.Semantic proximity Read ↗

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.Semantic proximity Read ↗

MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitorsSemantic proximity Read ↗

Blockade of pro-fibrotic response mediated by the miR-143/-145 cluster prevents targeted therapy-induced phenotypic plasticity and resistance in melanomaSemantic proximity Read ↗

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in MelanomaSemantic proximity Read ↗

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.Semantic proximity Read ↗

Exosome-mediated MIR211 modulates tumor microenvironment via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanomaSemantic proximity Read ↗

Redirecting resistance evolution in <i> BRAF <sup>V600</sup> </i> melanoma by inhibition of the peroxiredoxin-thioredoxin systemSemantic proximity Read ↗

The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.